Nantahala Capital Management LLC purchased a new stake in Curis, Inc. (NASDAQ:CRIS – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,978,876 shares of the biotechnology company’s stock, valued at approximately $1,033,171,000. Nantahala Capital Management LLC owned about 94.68% of Curis at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of CRIS. Maverick Capital Ltd. grew its holdings in Curis by 7.8% during the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares during the period. Squarepoint Ops LLC increased its stake in Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 8,973 shares in the last quarter. Armistice Capital LLC increased its stake in Curis by 8.7% in the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after purchasing an additional 78,265 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares during the period. 29.97% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages have recently issued reports on CRIS. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. Wall Street Zen raised Curis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Zacks Research downgraded Curis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright reiterated a “buy” rating on shares of Curis in a report on Monday, August 17th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $43.00.
Curis Stock Performance
NASDAQ CRIS opened at $1.49 on Friday. The stock has a market cap of $3.11 million, a price-to-earnings ratio of -0.10 and a beta of 3.13. The business has a 50 day simple moving average of $4.45 and a 200 day simple moving average of $10.56. Curis, Inc. has a 52-week low of $1.40 and a 52-week high of $39.00.
Curis (NASDAQ:CRIS – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 2,365.94%. On average, analysts predict that Curis, Inc. will post -24.23 EPS for the current year.
About Curis
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.
Featured Stories
- Five stocks we like better than Curis
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS – Free Report).
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
